Middle-East & Africa Ophthalmology Therapeutics Market was worth $2.81 billion in 2018 and estimated to grow at a CAGR of 8.1%, to reach $4.51 billion by 2023.Ophthalmology is the science associated with the treatment of eye defects and diseases. Recent advancements in genetics and stem cell biology are progressively boosting the potential for ophthalmology therapeutics.
Middle-East & Africa market for Ophthalmology Therapeutics is driven by the growing prevalence for vision impairment. Advancements in the field of medicine is also a key factor driving the growth of the market. Increasing geriatric population around the region along with an increase in the disposable income of the people are some of the other driving factors for the Ophthalmology Therapeutics Market. However, limited awareness about the diseases associated with ophthalmology is the key restraint for the growth of the market. Uncertain reimbursement policies and stringent regulatory framework are some of the other factors restraining the growth of the market.
Middle-East & Africa Ophthalmology Therapeutics market is broadly categorized into Indication and End User. Based on indication Middle-East & Africa Ophthalmology Therapeutics market is segmented into Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis. Glaucoma is the largest indication segment accounting for a share of approximately XX% followed by AMD with a share of XX%. On the basis of end user, the market is segmented into Hospitals, Eye Clinics, Diagnostic Centres and Patients. Hospitals account for the largest share of the market with a percentage share of approximately XX% while Diagnostics Centres is the fastest growing segment with a CAGR of XX%.
Based on geography, Middle-East & Africa Ophthalmology Therapeutics market is segmented into Middle-East and Africa. Middle-East is the largest market for Ophthalmology Therapeutics due to high disposable income of the people. Africa is estimated to be the fastest growing region with a CAGR of xx% during the forecast period of 2018-2023.
Some of the major companies covered in the report are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche, Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indication
5.1.1 Glaucoma
5.1.2 Dry Eye Syndrome
5.1.3 Diabetic Retinopathy
5.1.4 Retinal Vein Occlusion
5.1.5 Age-Related Macular Degeneration (AMD)
5.1.6 Macular Edema
5.1.7 Allergic Conjunctivitis
5.2 By End User
5.2.1 Hospitals
5.2.2 Eye Clinics
5.2.3 Diagnostic Centers
5.2.4 Patients
6. Geographical Analysis
6.1 Introduction
6.2 Middle-East
6.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Allergan, Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Merck & Co Inc
9.3 Pfizer
9.4 Roche
9.5 Novartis (Alcon)
9.6 Valeant
9.7 Regeneron
9.8 Santen
9.9 Bayer
9.10 Senju
9.11 Lpath
9.12 Eye Gate Pharmaceuticals
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
